Company news
Ovid Therapeutics Inc. (NASDAQ:OVID) news
Ovid Therapeutics Inc. news releases on 6ix. Latest, Sep 3, 2026: Ovid Therapeutics to Participate in Upcoming Investor Conferences
Press releases & updates
Ovid Therapeutics to Participate in Upcoming Investor Conferences
September 3, 2026
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
August 13, 2026
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
July 8, 2026
Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors
June 3, 2026
Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
May 12, 2026
Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
April 7, 2026
Ovid Therapeutics Announces Pricing of $60 Million Private Placement
March 17, 2026
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
March 17, 2026
Ovid Therapeutics to Participate in Upcoming Investor Conferences
February 24, 2026
Ovid Therapeutics Reports Phase 1 results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2, OV350 Intravenous
December 19, 2025
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
December 18, 2025
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
December 2, 2025
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
November 12, 2025
QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer
November 10, 2025
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
October 3, 2025
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
October 3, 2025
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results
August 13, 2025
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference
July 23, 2025
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
June 25, 2025
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
June 5, 2025
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results
May 13, 2025
Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
April 2, 2025
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
March 11, 2025
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
March 3, 2025
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
February 27, 2025
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 4, 2025
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting
December 1, 2024
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
November 11, 2024
Ovid Therapeutics to Host Investor Event
October 30, 2024
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin
September 25, 2024
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
September 10, 2024
Ovid Therapeutics to Present at Upcoming September Investor Conferences
September 3, 2024
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
August 12, 2024
Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer
August 7, 2024
Ovid Therapeutics to Present at Upcoming August Investor Conferences
July 29, 2024
Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
July 22, 2024
eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
July 9, 2024
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
June 30, 2024
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
June 16, 2024
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
May 13, 2024
Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 12, 2024
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 3, 2024
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
March 7, 2024
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
February 27, 2024
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 5, 2024
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
November 30, 2023
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
November 2, 2023
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
October 17, 2023
Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
October 9, 2023
Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
September 25, 2023